Suisse Life Science Group is a digital biological intelligence group headquartered in London with companies in Switzerland and in Brazil. Suisse Life Science is focused on creating, developing and managing Lifestyle Medicine and Life-Changing Digital Applications (iDDNA® technology) to maximize human performance:
Every two years, the world’s database doubles and every three years, health information also doubles. By 2020, global healthcare data will double every three days with 80% of the data being unstructured, with no clear relationship.
To truly get the results consumers deserve, health & wellness data needs to translate into accurate and actionable recommendations for both consumers and professionals.
Proprietary genetic panels, methods and life science knowledge base
Patent-pending proprietary bioinformatics algorithms
Trademarks and patents
For example, the following Swiss patent filings:
Suisse Life Science manages its services on a proprietary custom genotyping panel designed on Affymetrix Precision Medicine v2 DTC Axiom Array.
Suisse Life Science’s genetic panel is currently the broadest lifestyle genetic panel in the world and the most comprehensive array focused only on qualitative interpretation of the root causes of aging.
The Affymetrix Precision Medicine (PM) array technology platform incorporates multiple content categories, including a genome wide association study (GWAS) panel of markers for genome wide coverage in major ethnic groups, rare coding SNPs and indels for exome analysis, pharmacogenomic markers, eQTLs, and newly discovered loss-of-function variants, including sequence insertions and deletions from recent exome sequencing initiatives, totaling ~820,000/975,000 SNPs.
Affymetrix is now part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries.
Suisse Life Science’s custom chip was designed according to our R&D including:
Those genetic markers are individually interpreted according to
Generating a personal Genetic Positioning System (GPS).
Suisse Life Science’s GPS methods are grounded on published metabolic associations and scientific aging theories.
To run on the GeneTitan the custom Affymetrix Precision Medicine v2 DTC (DTC) Axiom Array, DNA is previously extracted from the samples using the Thermo King-Fisher Flex DNA extraction instrument utilizing Qiagen chemistry.
|Suisse Life Science Group Shareholders||Nationality|
|DEEPMIND Ventures Ltd.||49.56%||MT|
|Bonsai Capital Ltd.||18.00%||UK|
|Tamburi Investment Partners S.p.A.||2.36%||IT|
DEEPMIND Ventures is an investment company representing Suisse Life Science founders and top management.
Bonsai Capital Ltd. is a principal investor in early-stage Life Science companies, focused on start ups developing medicines, platform technologies, and diagnostics, addressing broad disease and condition areas
GDTRE Srl is an Italian private office and prime investor in lifestyle, fashion, food industry.
Tamburi Investment Partners S.p.A. is an Italian, independent investment-merchant bank focused on «excellent» companies (€ 1.4bn direct investments and club deals) – listed on FTSE MIB.